-
Non Regulatory April 1, 2025Vivesto reports positive Cantrixil results in an animal hematological cancer model
-
Regulatory March 31, 2025Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights
-
Regulatory March 18, 2025Vivesto licenses Apealea to China’s Zhida Pharmaceutical
Vivesto published its Q4 report for 2024 on February 20, 2025, at 08.00 am CET.